Literature DB >> 11210180

Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase.

D J Bacich1, J T Pinto, W P Tong, W D Heston.   

Abstract

Human Prostate Specific Membrane Antigen (PSMA), also known as folate hydrolase I (FOLH1), is a 750-amino acid type II membrane glycoprotein, which is primarily expressed in normal human prostate epithelium and is upregulated in prostate cancer, including metastatic disease. We have cloned and sequenced the mouse homolog of PSMA, which we have termed Folh1, and have found that it is not expressed in the mouse prostate, but primarily in the brain and kidney. We have demonstrated that Folh1, like its human counterpart, is a glutamate-preferring carboxypeptidase, which has at least two enzymatic activities: (1) N-acetylated alpha-linked L-amino dipeptidase (NAALADase), an enzyme involved in regulation of excitatory signaling in the brain, and (2) a gamma-glutamyl carboxypeptidase (folate hydrolase). The 2,256-nt open reading frame of Folh1 encodes for a 752-amino acid protein, with 86% identity and 91% similarity to the human PSMA amino acid sequence. Cells transfected with Folh1 gained both NAALADase and folate hydrolase activities. Examination of tissues for NAALADase activity correlated with the mRNA expression pattern for Folh1. Fluorescent in situ hybridization (FISH) revealed Folh1 maps to only one locus in the mouse genome, Chromosome 7D1-2.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11210180     DOI: 10.1007/s003350010240

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  54 in total

1.  Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption.

Authors:  Tiancheng Liu; Lisa Y Wu; Clifford E Berkman
Journal:  Cancer Lett       Date:  2010-05-08       Impact factor: 8.679

2.  Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling.

Authors:  William M Rockey; Frank J Hernandez; Sheng-You Huang; Song Cao; Craig A Howell; Gregory S Thomas; Xiu Ying Liu; Natalia Lapteva; David M Spencer; James O McNamara; Xiaoqin Zou; Shi-Jie Chen; Paloma H Giangrande
Journal:  Nucleic Acid Ther       Date:  2011-10       Impact factor: 5.486

3.  Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors.

Authors:  James Kelly; Alejandro Amor-Coarasa; Shashikanth Ponnala; Anastasia Nikolopoulou; Clarence Williams; David Schlyer; Yize Zhao; Dohyun Kim; John W Babich
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-06       Impact factor: 9.236

4.  Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen.

Authors:  Tiancheng Liu; Jessie R Nedrow-Byers; Mark R Hopkins; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2011-10-04       Impact factor: 2.823

5.  Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617.

Authors:  Melanie Hohberg; Wolfgang Eschner; Matthias Schmidt; Markus Dietlein; Carsten Kobe; Thomas Fischer; Alexander Drzezga; Markus Wild
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

6.  Identification of a gene frequently mutated in prostate tumors.

Authors:  D J Reding; K Q Zhang; S A Salzman; J V Thomalla; R E Riepe; B K Suarez; W J Catalona; J K Burmester
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

7.  Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody.

Authors:  Kar Muthumani; Liron Marnin; Sagar B Kudchodkar; Alfredo Perales-Puchalt; Hyeree Choi; Sangya Agarwal; Veronica L Scott; Emma L Reuschel; Faraz I Zaidi; Elizabeth K Duperret; Megan C Wise; Kimberly A Kraynyak; Kenneth E Ugen; Niranjan Y Sardesai; J Joseph Kim; David B Weiner
Journal:  Cancer Immunol Immunother       Date:  2017-08-17       Impact factor: 6.968

8.  Substrate specificity of prostate-specific membrane antigen.

Authors:  Marc O Anderson; Lisa Y Wu; Nicholas M Santiago; Jamie M Moser; Jennifer A Rowley; Erin S D Bolstad; Clifford E Berkman
Journal:  Bioorg Med Chem       Date:  2007-08-11       Impact factor: 3.641

9.  Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.

Authors:  Shawn M Hillier; Kevin P Maresca; Frank J Femia; John C Marquis; Catherine A Foss; Nghi Nguyen; Craig N Zimmerman; John A Barrett; William C Eckelman; Martin G Pomper; John L Joyal; John W Babich
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

10.  Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen.

Authors:  Lisa Y Wu; Jacinda C Do; Marat Kazak; Helen Page; Yoko Toriyabe; Marc O Anderson; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2007-10-30       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.